

1 **Improving the health of people experiencing homelessness with recent drug overdose: rationale for**  
2 **and design of the Pharmacist and Homeless Outreach worker Engagement Non-medical**  
3 **Independent prescribing Rx (PHOENIx) pilot randomised controlled trial**

4

5 ISRCTN 10585019

6

7 Richard Lowrie<sup>1\*</sup>, Andrew McPherson<sup>1</sup>, Frances S Mair<sup>2</sup>, Donogh Maguire<sup>3</sup>, Vibhu Paudyal<sup>4</sup>, Becky  
8 Blair<sup>1</sup>, David Brannan<sup>5</sup>, Jane Moir<sup>1</sup>, Fiona Hughes<sup>1</sup>, Clare Duncan<sup>6</sup>, Kate Stock<sup>1</sup>, Natalia Farmer<sup>7</sup>, Becci  
9 Ramage<sup>1</sup>, Cian Lombard<sup>1</sup>, Steven Ross<sup>8</sup>, Ailsa Scott<sup>8</sup>, George Provan<sup>8</sup>, Laura Sills<sup>9</sup>, Jennifer Hislop<sup>10</sup>,  
10 Andrea Williamson<sup>11</sup>

11

12 <sup>1</sup>Pharmacy Services, NHS Greater Glasgow and Clyde, Scotland, UK; <sup>2</sup>General Practice and Primary Care, Institute of Health  
13 and Wellbeing, College of Medical, Veterinary and Life Sciences, University of Glasgow, Scotland, UK; <sup>3</sup>Emergency  
14 Medicine, Glasgow Royal Infirmary, Scotland; <sup>4</sup>School of Pharmacy, University of Birmingham, England, UK. <sup>5</sup>Marie Trust,  
15 Glasgow. <sup>6</sup>Addictions Psychiatry, NHS Ayrshire and Arran, Scotland; <sup>7</sup>Department of Social Work, School of health and life  
16 sciences, Glasgow Caledonian University, Glasgow. <sup>8</sup>Simon Community Scotland Street Team, Scotland, UK. <sup>9</sup>East End  
17 Addictions Services, NHS Greater Glasgow and Clyde; <sup>10</sup>Healthcare Improvement Scotland <sup>11</sup>Alcohol and Drug Recovery  
18 Service, Glasgow Health and Social Care Partnership; <sup>11</sup>Undergraduate Medical School, School of Medicine, Dentistry and  
19 Nursing, College of Medical, Veterinary and Life Sciences, University of Glasgow.

20

21 \*Corresponding author: Richard Lowrie, Lead Pharmacist, Homeless Health / Research and  
22 Development, NHS Greater Glasgow and Clyde, Glasgow, G76 7AT, Scotland, United Kingdom. Tel:  
23 +44 07971827565, email: [Richard.Lowrie@ggc.scot.nhs.uk](mailto:Richard.Lowrie@ggc.scot.nhs.uk)

25 **ABSTRACT**

26 **Introduction**

27 Numbers of People Experiencing Homelessness (PEH) are increasing worldwide. Systematic reviews  
28 show high levels of multimorbidity and mortality due to treatable diseases including drug overdose.  
29 Integrated health and social care outreach interventions may improve outcomes. No previous studies have  
30 targeted PEH with recent drug overdose despite their high recorded levels of drug related deaths. There  
31 are few data on health and social care problems. Feasibility work suggests a collaborative health and  
32 social care intervention (Pharmacist and Homeless Outreach Engagement Non-medical Independent  
33 prescriber Rx-PHOENIx) is potentially beneficial. We describe the methods of a pilot randomised  
34 controlled trial(RCT) with parallel process and economic evaluation in PEH with at least one drug-related  
35 overdose in the preceding 6 months.

36 **Methods**

37 Detailed health and social care information will be collected at baseline before 1:1 randomisation to: care-  
38 as-usual plus visits from a pharmacist and homeless outreach worker (PHOENIx) for 6-9 months; or care-  
39 as-usual. The main outcomes are rate of presentations to emergency department(ED) for overdose or other  
40 causes and whether to progress to a definitive RCT based on: recruitment of  $\geq 100$  participants within 4  
41 months; $\geq 60\%$  patients remaining in the study at 6 and 9 months follow up; $\geq 60\%$  of patients in the  
42 PHOENIx group receiving the intervention; and $\geq 80\%$  of patients with data collected. Secondary  
43 outcomes include: hospitalisations; treatment uptake and patient reported measures. Semi-structured  
44 interviews will explore future implementation of PHOENIx, and reasons for overdose and protective  
45 factors. An economic evaluation will assess the feasibility of conducting a cost effectiveness analysis in a  
46 subsequent definitive trial.

47 **Discussion:** The study will determine whether to proceed to a definitive RCT for PEH aiming to fulfil  
48 unmet health and social care needs of those experiencing homelessness and at risk of drug related harms  
49 and deaths while providing useful insights into barriers and facilitators to PHOENIx and characterising  
50 the health and social care needs of PEH.

51 **Ethics and dissemination:** The trial was approved by the South East Scotland National Health Service  
52 Research Ethics Committee 01. Results will be available in the last quarter of 2022.

53 **Registration details:** The trial is registered with the UK Clinical Trials Registry (ISRCTN 10585019).

54 **Strengths and limitations of the study**

- 55 - We plan to recruit patients normally excluded from intervention trials and collect a diverse health  
56 and social care dataset at baseline
- 57 - The 6-9 month individualised, complex intervention offers longer consultations, integrated  
58 continuous, health and social care support on outreach
- 59 - Mixed methods will enable determination of whether a subsequent trial is merited from an  
60 efficacy, economic and patient perspective.
- 61 - By design, the pilot randomised controlled trial lacks the power to detect a clinically significant  
62 effect and recruitment was limited to 20 locations in Scotland's largest city

63

64 **Keywords:** Pharmacy, Homelessness, randomised controlled trial, problem drug use.

65

66

67 **INTRODUCTION**

68 **Background**

69 Homelessness is a global problem, and the number of people experiencing homelessness (PEH) is  
70 increasing worldwide.<sup>1</sup> The individual, societal, health and economic burden of homelessness is widely  
71 known and undisputed.<sup>2</sup> The health of PEH is characterised by problems with mental health, physical  
72 health, drug and alcohol use and PEH tend to die prematurely aged 41-51 years, with numbers of long  
73 term conditions on a par with housed individuals almost twice their age.<sup>3-6</sup> A majority of PEH experience  
74 problem poly drug use, and associated high rates of deaths through overdose.<sup>7,8</sup> Other causes of death are  
75 also increasing.<sup>5</sup> Homelessness is an independent risk factor for hospital admission and emergency  
76 department (ED) attendance and rates of ED use are increasing across healthcare systems worldwide.<sup>2</sup>  
77 PEH are known to present to ED late and with comparatively more serious problems.<sup>2,9</sup> PEH can be  
78 overwhelmed by their multiple health and social care problems and lack of support, experiencing  
79 individual, structural and institutional difficulties with self-care.<sup>10-13</sup>

80  
81 The development and testing of complex, integrated health and social care interventions has been  
82 highlighted as an important priority with the associated need to test the impact of longer contact times.<sup>2,4,</sup>  
83 5, 14, 16

84  
85 **Complex interventions for multiple problems**

86 Assertive outreach delivered by workers who can establish trust and develop positive interpersonal  
87 relationships is an evidenced approach to strengthening primary health and social care for PEH.<sup>14-17</sup>  
88 Partnerships should be built between outreach health services and homeless service providers who are  
89 best placed to support wider needs including housing, education and employment.<sup>14</sup> PEH perspectives on  
90 effective components of interventions include: involvement of peer workers in outreach programmes; help  
91 with housing; welfare payments and social prescribing.<sup>9, 14, 18, 19</sup> Interventions limited to addressing single

92 health problems e.g. problem drug use, or mental health problems, may hold little appeal for PEH who  
93 have multiple problems.<sup>2, 15</sup>

94 Interventions in published studies offered housing improvements for PEH with mental health or substance  
95 misuse, or target and address single physical health conditions e.g. HIV or Tuberculosis without  
96 addressing multimorbidity<sup>16, 19-23</sup> or diseases thought to be amenable to early intervention e.g.  
97 cardiovascular or respiratory disease.<sup>5</sup> Of the few robust studies of interventions led by healthcare  
98 professionals aiming to improve broad outcomes e.g. mortality or reduced ED utilisation, none have been  
99 found to be effective.<sup>23</sup> Interventions to address multiple needs in PEH are necessarily complex, with a  
100 new framework supporting rigorous, phased testing.<sup>24</sup> We are not aware of studies having following the  
101 recommended development stages for testing of complex interventions, including pilot testing to inform  
102 power and sample size calculation for a subsequent definitive trial.<sup>19, 24, 25</sup> There are no UK based  
103 intervention studies targeting community based PEH.<sup>23</sup>

104

### 105 **A role for pharmacists collaborating with third sector homeless workers**

106 Generalists may be best equipped to address the diverse levels of multimorbidity experienced by PEH,<sup>4,</sup>  
107 <sup>15, 16</sup> suggesting the testing of holistic medical plus social care on outreach for community dwelling PEH is  
108 overdue. However, as workforce shortages worsened by COVID-19 may limit expansion of roles of  
109 established primary care clinicians, there may be a role for pharmacists with generalist independent  
110 clinical prescribing qualifications. Generalist Pharmacist independent prescribers exist across the world,  
111 offering a potential solution to ongoing General Practitioner and Nurse workforce shortages.<sup>26</sup> Over 7500  
112 (13%) of UK based pharmacists have undergone additional subsequent training in therapeutics and  
113 completed a period of additional supervised clinical training, to gain an independent prescribing  
114 qualification. This independent prescribing qualification enables diagnosis and prescribing for any  
115 condition within the pharmacist's competency. In the UK, Pharmacists practise as part of the  
116 multidisciplinary health team throughout primary care (in community pharmacies as independent  
117 contractors or based in General Practice offices as clinical pharmacists) and secondary care. A

118 collaboration between Pharmacists and third sector homeless workers is likely to be welcomed by PEH. <sup>10</sup>  
119 Emerging evidence of under-treatment with medicines <sup>3, 6</sup> and challenges to medicine adherence, <sup>27</sup> which  
120 may be amenable to pharmacist intervention <sup>28, 29</sup> both of which may contribute to poor health and  
121 premature death in PEH, <sup>2, 5</sup> suggests a need to robustly test pharmacist led integrated health and social  
122 care intervention for PEH.

123

## 124 **PHOENIx**

125 Staff working for homeless charities in Glasgow, Scotland (The Simon Community Scotland and The  
126 Marie Trust) have lived experience of homelessness and formed a novel, integrated National Health  
127 Service – Homeless sector partnership called PHOENIx: **P**harmacist and **H**omeless **O**utreach  
128 **E**ngagement and **N**on-medical **I**ndependent prescribing **R**x.<sup>30-32</sup> The PHOENIx team assertively outreach  
129 to various locations in Glasgow e.g. homeless congregate accommodation, to engage and offer holistic  
130 assessment, treatment, prescribing and referral for patients’ expressed health and social care priorities. <sup>30-</sup>  
131 <sup>32</sup> PHOENIx is a secondary prevention intervention aiming to improve self-care and strengthen primary  
132 care to reduce the use of ED. The Pharmacist is from the National Health Service and the third sector  
133 outreach worker is from either of Glasgow’s homeless charities (Simon Community Scotland or the Marie  
134 Trust). Visiting patients once weekly, and with consultations lasting an hour on average, previous  
135 qualitative work suggests benefit to patients <sup>33</sup> and a feasibility study describes the pharmacist assessing,  
136 treating and prescribing for acute and chronic health problems, while the homeless charity link worker  
137 addresses benefits, housing and social prescribing.<sup>32</sup> Working within the clinical governance framework  
138 provided by the patient’s GP and the local ED, PHOENIx may improve health and reduce emergency  
139 health service contacts. <sup>32, 33</sup>

140

## 141 **PHOENIx after overdose pilot randomised controlled trial**

142 Here, we describe methods from an ongoing pragmatic pilot randomised controlled multicentre trial with  
143 embedded economic and qualitative evaluation, of PHOENIx intervention targeting PEH with recent non-

144 fatal drug overdose. The trial aim is to determine whether progression to a subsequent definitive  
145 randomised controlled trial is justified based on: reduction in ED visits; rate of participant recruitment and  
146 retention at 6 and 9 month follow up; fidelity of intervention delivery; and sufficient data collection at  
147 baseline and 6 and 9 month follow up. Given the paucity of data informing research and service delivery,  
148 we will also collect a diverse range of patient level health and social care data. Secondary outcome data  
149 include measures of overdose occurrence, healthcare utilisation, acceptability, and patient reported  
150 outcomes (e.g. quality of life/perceived burden of treatment/levels of anxiety/depression).

151

152

## METHODS

### 153 Study setting

154 NHS Greater Glasgow and Clyde (GG&C) provides free primary, secondary and tertiary care to  
155 approximately 1.2 million people (almost 25% of the Scottish population). Prior to the COVID-19  
156 pandemic, there were an estimated 7000 PEH in Glasgow every year with an estimated 560 rough  
157 sleeping annually, both proportions higher than in the rest of the UK.<sup>30</sup> The study is set in 20 Glasgow  
158 venues (homeless accommodation or drop in centres).

159

### 160 Eligibility criteria

#### 161 Participants

162 Homeless individuals<sup>14</sup> aged 18 years and over are considered eligible if they have at least one drug  
163 overdose in the previous 6 months (Table 1).

164

165 **Table 1: Trial Inclusion and Exclusion Criteria**

166

| Inclusion Criteria   | Exclusion Criteria  |
|--|---|
| Legally homeless (living in temporary homeless accommodation, rough sleeping or threatened with homelessness)<br>and<br>Aged 18 years and over | Living in residential or community based rehabilitation facility which has direct access to in-house medical and nursing care<br>or |

|   |   |
|---|---|
| and<br>One or more non prescribed drug overdoses in past six months confirmed by self-report and witnessed overdose/ambulance call out/ED visit /naloxone use | Unable to give written informed consent |
|---|---|

167

168 **PHOENIx team**

169 The PHOENIx team comprise five part-time NHS Greater Glasgow and Clyde employee pharmacists  
170 working in pairs with four part-time Homeless charity link workers (from The Simon Community  
171 Scotland or The Marie Trust) available Monday to Friday, between the hours of 9am -6pm. Pharmacists  
172 are within the governance of a Homeless Health Service General Practice and a major teaching hospital in  
173 the city (Glasgow Royal Infirmary) ED clinical staff who provide clinical support. PHOENIx offers  
174 holistic, first contact, continuous primary health and social care, understanding that motivation fluctuates,  
175 and patients' trust in care providers is usually low due to previous traumatic life experiences e.g. assault,  
176 abuse, or stigma.

177 Pharmacists in the PHOENIx team had undergone additional training and passed a theory and practical  
178 examination in therapeutics and clinical assessment, to qualify as independent prescribers, able to  
179 prescribe any medicine within their competency. Pharmacists carry a kit bag containing: a prescription  
180 pad; laptop for accessing clinical records; mobile phone; basic clinical equipment for common clinical  
181 assessments; medicines for emergency purposes (salbutamol, aspirin, glyceryl trinitrate spray); wound  
182 care products; lists of relevant health and social care contacts; naloxone and clean injecting equipment.

183 They have read and write access to patients' clinical records (addictions/mental health teams, Homeless  
184 Health Service General Practice Hospital, community pharmacy dispensing) and the third sector  
185 Homeless link worker has read and write access to wider third sector contacts. Working in pairs, the team  
186 gather as much information as possible about each patient on first meeting, using medical and third sector  
187 charity records, to understand the patient's priorities and inform an individualised intervention and in case  
188 of any known risks. The pharmacist conducts a clinical assessment, then prescribes, refers or treats  
189 patients on the spot.



190 The Homeless link workers remain employed as part of their parent charity organisation, although have  
191 NHS honorary contracts. During consultations, the link worker offers to maximise the patient's incoming  
192 financial benefits, improve access to better accommodation, encourage participation in social activities  
193 and generally problem solve where possible in any other aspect of the patient's shared story while  
194 building a therapeutic relationship.

195 In addition to clinical/technical expertise, selection procedure at interview for PHOENIX staff included  
196 demonstration of empathy, non-judgemental attitude and active listening.

197

## 198 **Interventions**

### 199 **Usual care**

200 In Scotland, PEH are offered a temporary single room in a designated city centre venue e.g. hotel, hostel  
201 or bed and breakfast accommodation, and allocated a named case worker.

202 Patients with problem alcohol or substance use may receive care and treatment from Glasgow's Alcohol  
203 and Drug Recovery Service (ADRS) or the Homeless Addictions Team (HAT) or the Heroin Assisted  
204 Treatment service. Patients can present to any ADRS seeking help and receive same day assessment. In  
205 some circumstances following management of any immediate care needs they may be supported to  
206 engage with another ADRS closer to their temporary accommodation or to which they remain open from  
207 a previous treatment episode. If transport to a different base is required at the time they present the service  
208 will offer a taxi to facilitate this journey. For people already open to drug and alcohol services their care  
209 and treatment is provided through a combination of phone and face to face contact either at the base or on  
210 outreach, dependent on individual needs and circumstances.

211 To access primary health care including a General Practitioner, or ADRS, PEH must either travel to their  
212 registered mainstream or specialist homelessness General Practice or phone, which requires PEH to have  
213 access to a mobile phone (which can be supplied by ADRS or HAT) or use a landline within their  
214 accommodation, if appropriate. All mainstream services operated triage during COVID-19 lockdown,  
215 with requests for patients to phone the relevant care team prior to presenting at the premises, if possible.

216

217 The Homeless Health Service GP practice offered phone inreach to a variety of homeless accommodation  
218 services and restarted outreach after a period of interruption.

219

220 For patients with mental health problems without problem drug use, access is through General  
221 Practitioner referral to general mental health services or a request for support via ADRS if currently  
222 linked in for treatment of problem substance use.

223

224 Clinical records for PEH are spread across three or four different platforms because different clinical  
225 teams (emergency care, specialist Homeless GP, mainstream GP, ADRS and mental health, social care)  
226 are distinct, each record system with different access privileges used by staff within each team. The  
227 Pharmacists in the PHOENIx team obtained permissions to remotely access all possible health and social  
228 care records on outreach, to understand all of the patients' previous health and social care history and  
229 relieve patients of the burden of repeating their traumatic stories again, and for safety reasons.

230

231 In the UK, the out-patient (ambulatory) management of PEH with chronic diseases takes place either  
232 solely in primary care or between primary care and Hospital based out-patient clinics. During COVID-19  
233 lockdowns most out-patient appointments were switched to phone or on line video consultations which  
234 may or may not have been possible for PEH. Patients in need of urgent hospital care self-present or may  
235 be referred by their GP or others to a hospital ED from where they may be admitted to hospital or  
236 discharged back to primary care. Prescribing is undertaken by GPs, and independent prescribers e.g.  
237 pharmacists or nurses with advanced clinical skills and knowledge. All prescriptions are obtained free of  
238 charge from community pharmacies. The capacity for outreach from services that PEH use is variable  
239 across the city.

240

241 **Intended purpose of the PHOENIx intervention**

242 The PHOENIx intervention aims to decrease emergency service use, and overdoses, by increasing access  
243 to holistic preventative primary health care and improving the socioeconomic factors associated with  
244 homelessness e.g. income, housing. Offering weekly visits, on assertive outreach and through persistent  
245 follow up, PHOENIx aims to provide ‘whole person’ help for all health and social care needs: physical  
246 health; mental health; problem drug use; benefits; accommodation; and social prescribing.<sup>30-33</sup> Access to  
247 the team for any reason, was facilitated by a dedicated phone number which patients could call anytime,  
248 or through the staff working for the Simon Community Scotland or the Marie Trust, who facilitated  
249 contacts face to face. The team do not discharge any patient and all contacts were in addition to the  
250 patient’s usual care. If the team cannot locate patients they enquire in accommodation or other venues or  
251 through contacts within homeless charities or statutory services, to help track PEH.

252 The team are aware of barriers to accessing care among PEH, and the problems posed by segmentation of  
253 services, so they adopted a person-centred, trauma informed approach. A comprehensive health and social  
254 care assessment is offered on the first meeting with each patient unless the patient’s priorities take the  
255 conversation in another direction, in which case the assessment is conducted in stages thereafter. If the  
256 team are unable to provide direct health/social care help immediately, they problem solved with the  
257 patient, on the spot e.g. referred, or made an appointment on the patient’s behalf e.g. to attend an  
258 appointment with mental health team while booking transport and providing reminders. The PHOENIx  
259 team treat patients as equal partners in discussions about their treatment and wishes, asking patients to  
260 prioritise what they want help with over the course of weekly visits for at least 6 months. For example, if  
261 the patient does not want to tackle their drug use, this is not prioritised by the team. Instead, other  
262 priorities e.g. mental health problems, or respiratory function, or financial benefits, or changing  
263 accommodation, became the focus until the patient was ready to address their problem drug use. The team  
264 provides a variety of supports at different times depending on the patient’s needs including advocacy,  
265 clothing, emotional support, phones, books, shopping, furniture.<sup>31</sup> Patients injecting drugs will be  
266 routinely offered dry blood spot BBV testing, injecting equipment and naloxone at each visit. Pharmacy  
267 Services within NHS Greater Glasgow and Clyde will remain the Pharmacists’ employers throughout the

268 study: strong communication links between the pharmacists and all other clinical teams involved in the  
269 care of PEH minimised any theoretical clinical risks.

270  
271 The Intervention will be discontinued if the patient: loses capacity; enters a rehabilitation facility;  
272 becomes incarcerated and cannot not be reached in prison; becomes lost to follow up (some PEH flee  
273 violence and their whereabouts can suddenly change to prevent encounters with known assailants); or if  
274 the patient asks the team to stop offering the intervention.

275  
276 The study Principal Investigator will visit pairs of PHOENIX staff on outreach every month and receive  
277 feedback from teams to assess fidelity of the intervention against the intervention domains. The team will  
278 meet monthly to discuss progress and patient scenarios, forming a robust peer support network, with daily  
279 communication through an encrypted social media channel approved for use by NHS Greater Glasgow  
280 and Clyde. The pharmacists will meet with the Homeless Health Service GPs monthly to discuss difficult  
281 cases and seek advice when necessary from the Homeless Health GP service and consultants in the ED of  
282 the local hospital and homeless liaison nurses in the local hospital. There will be regular communication  
283 with ADRS/HAT staff.

284  
285 All other interventions and concomitant care are permitted throughout the trial.

286  
287 **Outcomes**

288 The co-primary endpoint is whether to progress to a definitive trial, based on any improvement in the rate  
289 of presentation to EDs for overdoses or other causes, during the 6 or 9 month follow up period, and  
290 achievement of the following progression criteria:

- 291 • recruitment of at least 100 patients within 4 months;
- 292 •  $\geq 60\%$  patients remaining in the study at 6 and 9 months follow up (excluding those who have  
293 died or lost capacity);

294 • establishment of the pharmacist intervention ( $\geq 60\%$  of patients in the intervention group receiving  
295 the intervention as planned excluding those who have died or lost capacity);

296 •  $\geq 80\%$  of patients with data collected as planned (excluding those who have died or lost capacity).

297 Secondary outcomes are as outlined below, compared between Intervention and Usual care groups at 6  
298 and 9 month follow up:

299 1. Health care utilisation which includes number of (and number of patients with):

300 • Non prescribed drug overdoses;

301 • hospital admissions;

302 • prescribing for multimorbidity (proportion of patients prescribed medicines for diagnosed conditions;  
303 proportion of patients with minimum doses of medicines for diagnosed conditions);

304 • contacts (phone or face to face) with GP/nurse/addictions worker/other healthcare professional;

305 • Scottish Ambulance Service call outs;

306 • missed out-patient appointments.

307 2. Time from randomisation until: first ED visit for OD and other reasons; death; and hospitalisation.

308 3. Patient reported measures:

309 • EuroQol 5D 5L quality of life score <sup>34</sup>

310 • Patient Experience with Treatment and Self-management measure (PETS)<sup>35</sup>

311 • Frailty score <sup>36</sup>

312 • Anxiety/depression ratings

313 • Modified MRC breathlessness scale

314


315 Outcomes will be collected by independent researchers interviewing patients and accessing NHS clinical  
316 records at 6 and 9 month follow up compared between the intervention and usual care groups.

317 Intervention acceptability will also be measured through a parallel qualitative evaluation.

318

319 **Participant timeline**

# Time schedule for enrolment, interventions, assessments and visits for participants



320

321 **Sample size**

322 The guidance on sample sizes for pilot studies varies with 30-50 patients per arm thought to be sufficient,  
 323 because the focus is on estimating parameters for the full study, rather than formal testing of hypotheses.<sup>37</sup>  
 324 We aimed to invite approximately 160 patients, anticipating a recruitment rate of ~60% based on our earlier  
 325 feasibility study.<sup>32</sup> If 100 agree to participate, we estimate the recruitment rate as 62.5% (95% CI 55%-  
 326 70%). Mortality rate in our previous feasibility study was 8.3% over one year, therefore we anticipated 6  
 327 patients dying over 9 months.<sup>32</sup> Assuming a conservative retention rate of 70% after 9 months, and  
 328 additional losses due to mortality, we anticipate at least 64 patients with 6 and 9 month follow up data to  
 329 inform sample size for a full scale randomised controlled trial.

330

331 **Recruitment**

332 **The importance of researcher ‘fit’**

333 Induction training will include visits to potential study sites in Glasgow, and introductions to  
334 accommodation staff and third sector street homeless outreach workers were in different venues.  
335 Processes for obtaining consent and baseline and follow up interviews and data collection will also be  
336 explained and rehearsed. The researchers comprise a qualified mental health nurse with more than 20  
337 years of experience in front line NHS service delivery and research with PEH, and those experiencing  
338 problem substance use and poor mental health; and a pharmacy technician with over 20 years' experience  
339 in patient services (mental health and general hospitals).

340

#### 341 **Process**

342 Researchers will visit accommodation and other venues, to approach all potentially eligible patients, face  
343 to face. Patient self-report of overdose will be confirmed by examination of clinical records and/or  
344 testimony from witnesses e.g. accommodation staff, friends, or injecting/drug using partners.  
345 Confirmation included ambulance call out, naloxone administration recorded in clinical notes or in-house  
346 patient records made by accommodation providers, or an ED visit for overdose. Researchers will ask each  
347 potential recruit about the circumstances of the overdose, and when this occurred, including whether the  
348 patient had any recollection of having received any assistance from other people at the time of overdose.  
349 This approach to identifying eligible patients will be taken because our collective clinical experience  
350 suggested most non-fatal overdoses are not formally recorded or if recorded, there is no standardised,  
351 identifiable coding applicable across different clinical / administrative records. Patients will be offered a  
352 non cash incentive (voucher for use in a city centre store not selling alcohol or tobacco) of £10 (equivalent  
353 to 13 US dollars or 12 Euros) on completion of baseline data collection, and after completion of each  
354 follow up data collection at months 6 and 9. The baseline interview pro-forma is shown in Supplementary  
355 information.

356

#### 357 **Methods: assignment of interventions**

358 **Allocation: sequence generation** One hundred and sixty sealed opaque envelopes will be generated  
359 remotely by staff from the University of Birmingham not directly involved in participant recruitment.  
360 Each envelope will contain a folded piece of paper with the computer generated printed words:  
361 ‘PHOENIx Intervention’ or ‘Usual care’. The envelopes will be randomly shuffled, by staff from the  
362 University of Birmingham then sent in a box, by secure mail, to the Glasgow study centre before the first  
363 patient is recruited. This is an individual level randomisation approach without stratification.

364 **Allocation concealment mechanism and implementation** Researchers will take informed consent by  
365 discussing the patient information leaflet with patients, explaining what the study entails, and asking if the  
366 patient would want to participate. Some patients will read the information and make the decision  
367 themselves. In both cases, patients will have time to read the information or have it explained to them, and  
368 ask questions before coming to a decision. Researchers will conduct baseline interviews in person with  
369 participants in different venues in Glasgow city centre. At the end of the interview researchers will phone  
370 the study centre asking for a randomisation. One of the research team will answer the call immediately  
371 and, in the presence of another member of the research team, pick an envelope at random from the box of  
372 envelopes. The research team will request the following information from the researcher: patient name;  
373 date of birth and location. A sequential study number will be written on the outside of the chosen  
374 envelope and, in the presence of another member of the research team, and while the researcher remains  
375 on the phone, the envelope will be opened and the allocation revealed to the researcher (and patient) on  
376 the phone after two members of the research team read the allocation from the piece of paper inside the  
377 envelope. The study team will return the piece of paper inside the envelope then write the words  
378 ‘Intervention’ or ‘Usual care’ onto the outside of the envelope together with the date and store the  
379 envelope inside a folder (one folder per patient), inside a lockable filing cabinet within the study centre.  
380 Participants will therefore be randomised in a one-to-one ratio to ‘usual care’ or ‘PHOENIx intervention’.  
381 On allocation to Intervention, the patient’s details and location will be communicated to the PHOENIx  
382 team who will be asked to contact the patient and begin offering the intervention.

383



384 Following allocation to usual care, participants will have no further contact from study personnel until  
385 follow up data collection.

386 **Blinding** Independent statisticians conducting analysis of follow up data will be blinded to allocation.

387 Assessment of outcomes from clinical records will be conducted by a researcher / administrator who will  
388 be blind to assignment to intervention or usual care group.

389

### 390 **Data collection, management and analysis**

391 Baseline, six and nine month follow up data will be collected during researcher led face to face patient  
392 interviews in the patient's accommodation, or in homeless charity drop in centres in Glasgow city centre.

393 Interviews will last approximately 45 minutes. Study instruments used during interviews e.g. weighing  
394 scales, peak flow meters, were used routinely during clinical care in primary and secondary care, and  
395 familiar to researchers.

396 Data to be collected (Supplementary information) include: details of comorbidities; non prescribed drug  
397 use; prescribed medicines; health related quality of life using EQ-5D-5L; weight; height; Blood pressure;  
398 Pulse; Peak Expiratory Flow rate; modified Medical Research Council Dyspnoea scale; COPD Assessment  
399 Test; grip strength, GP visits, nurse visits, ADRS and mental health team and other primary healthcare  
400 contacts; un/scheduled secondary healthcare contacts including missed out patient appointments; Fried's  
401 Adapted frailty phenotype questions and an adapted version of the Patient Experience with Treatment and  
402 Self-Management (PETS) measure.

403 The intervention team will record all treatment administered e.g. dressings changes, prescriptions issued,  
404 referrals; advice given; gifts and kindness e.g. personal support in form of clothing or food; advocacy and  
405 type (face to face or phone call) of patient visits.

406 Validated questionnaires used during interviews have not previously been used in PEH, therefore, the  
407 research and clinical team evaluated their suitability in advance and decided only one needed modification:

408 The PETS.<sup>35</sup> Some aspects of the language used in the PETS and assumptions about how patients obtained  
409 their medicines and aspects of self-care were deemed potentially incomprehensible to PEH in Scotland,

410 which led to the research team making minor modifications, which were discussed with the questionnaire  
411 author. They included, for example, replacing the term “refill” in relation to medicines, to “get more of your  
412 medicines before they run out” or replacing “somewhat” with “neither easy nor difficult” or “monitor” with  
413 “keep tabs on” or “checking blood pressure” with “checking injection sites”. The section containing five  
414 questions about “Medical and healthcare expenses” was omitted because the health service in Scotland does  
415 not charge for care and all prescriptions are free.

416

417 Interview data will be recorded on paper data collection forms during interviews, prior to transcription onto  
418 an EXCEL spreadsheet by the research team. Prescribing, co-morbidities, laboratory test values, General  
419 Practitioner contacts and other healthcare utilisation data will be subsequently extracted from medical and  
420 ADRS team records and entered onto the same EXCEL spreadsheet. We therefore plan to utilise data from  
421 these two sources (patient reports and data from medical records) to provide a comprehensive picture.  
422 Members of the research team will cross check a 10% sample of data entries for accuracy and completeness.  
423 At 6 and 9 month follow up, the research team will make repeated attempts to re-engage patients, as will  
424 the PHOENIX team during the intervention phase. Repeated attempts will be made weekly and in addition  
425 to phone calls (if the patient has a phone) including: checking primary care clinical records for attendance  
426 at health and social care venues for appointments and meeting the patient at the appointment; checking  
427 emergency department and hospital records for presentations and changes to contact address and contact  
428 numbers or for change of status from having capacity to loss of capacity (reason for withdrawal from the  
429 trial) or death; phone/visit to community pharmacies to ask if the patient has attended for collection of  
430 prescription or for supervised opiate substitution treatment; phone/visit to the patient’s accommodation to  
431 enquire about the patient’s usual patterns of appearance; asking the homeless community hub staff if  
432 patient has attended; asking the third sector homeless outreach teams for possible sightings; and visiting  
433 the patient’s usual begging site. If patients cannot not be located, researchers will still be able to collect  
434 patient data from hospital records, General Practices and Alcohol and Drug Recovery Services as

435 appropriate. If patients die or lose capacity, data up until the point of death or loss of capacity, will be  
436 collected.

437

#### 438 **Statistical methods**

439 Outcome analysis will be conducted by independent statisticians at University of Birmingham after  
440 collection of 9 month follow-up data. Primary outcome measures will be described using proportions,  
441 along with 95% confidence intervals to describe uncertainty. Patient questionnaire and clinical measures  
442 will be analysed according to the intention to treat principles. Appropriate summary statistics (e.g.  
443 proportions & inter-quartile ranges, means and standard deviations) along with 95% confidence intervals  
444 will be generated for the study feasibility and patient reported / clinical / health utilisation measures. By  
445 design there is no a-priori powered endpoint, however hypothesis testing will be conducted to determine  
446 whether there is any difference between outcome measures. Between-group measures (mean differences  
447 and relative risks) will be reported with 95% confidence intervals.

448

#### 449 **Economic evaluation**

450 An embedded economic evaluation will examine the feasibility of determining the cost-effectiveness of the  
451 PHOENIX intervention in a subsequent definitive trial. The main analysis will consider a health and social  
452 care service perspective whereby unit costs are applied to each item of health (e.g. hospitalisation) and  
453 social care service use data. Unit costs will be taken from routine sources where possible including missed  
454 appointments.<sup>38-40</sup> The effectiveness of the intervention will be explored in terms of health state utilities  
455 (for a future cost utility analysis), as measured using the EQ-5D-5L to generate Quality Adjusted Life Years  
456 (QALYs) to be used alongside the cost data to give an indicative picture of cost-effectiveness. QALYs will  
457 be generated from the EQ-5D-5L using appropriate crosswalk methods and applying reference values for  
458 the EQ-5D-3L.<sup>41-43</sup> Both cost and utility outcomes will be quantified to describe the costs of the services  
459 and to provide QALY data, as currently few data on the QALY loss associated with homelessness are  
460 available.

461

## 462 **Qualitative evaluation**

463 In a parallel process evaluation, we will explore participant perspectives of their drug use and overdoses,  
464 including aspects of support perceived as most important in order to prevent subsequent drug overdose and  
465 their perceptions of the existing pathway for health and social care follow up post drug overdose together  
466 with their experience of the intervention. This will be conducted through qualitative face-to-face semi  
467 structured interviews with a purposive sample of 20-30 recruited patients in the intervention and usual care  
468 group in order to obtain a variety of experiences. Interviews will be conducted by an independent researcher  
469 (NF) who has no knowledge of patients prior to the interviews. All interviews will be conducted in a city  
470 centre drop in service utilised by PEH. Data will be gathered by recording face to face semi-structured  
471 interviews via an audio digital recording device and will be transcribed, using pseudonyms to ensure  
472 confidentiality and anonymity. All study participants will receive a £10 voucher as recognition for their  
473 participation. Thematic coding will be conducted by NF and then checked by members of the research team  
474 to reduce the risk of bias, ensure consistency and rigour. Normalisation Process Theory (NPT) will be used  
475 to inform conceptualisation of the process evaluation data because it is a theoretical framework used to aid  
476 development, evaluation and implementation of complex interventions. NPT is a theory that focuses on the  
477 “workability” of complex interventions in the real world.<sup>44</sup> We hypothesise that PEH may be  
478 “overwhelmed” by self-management tasks and will vary in their capacity to cope with any given level of  
479 treatment burden depending on a range of factors such as health literacy, language, drug seeking behaviour,  
480 level of educational attainment, personal beliefs, physical and mental abilities, and structural and practical  
481 barriers to accessing care. We will be looking at the issue of treatment burden with participants through a  
482 NPT lens and considering how the intervention affects individual capacity. Findings will be considered  
483 alongside quantitative outcomes (PETS, treatment burden measure) obtained as part of the secondary  
484 outcome measures.

485 This qualitative work will enable us to capture rich, complex data and unanticipated insights. Data will be  
486 analysed using NVivo V.12 software.<sup>45</sup>

487

## 488 **Data monitoring**

489 A multidisciplinary data monitoring committee involving researchers, NHS administrators and clinicians  
490 will have oversight of the qualitative and quantitative data collection process, and study methods,  
491 independent from the main study funder (Drug Death Task Force of the Scottish Government). The data  
492 monitoring committee will ensure researchers have access to relevant data, and study milestones are adhered  
493 to. No interim analyses are planned, and as the study intervention is offered in addition to usual care, with  
494 PHOENix supporting patients using guideline based care only, adverse events of the trial intervention are  
495 not anticipated. Trial conduct will be audited by NHS Greater Glasgow and Clyde Research and  
496 Development, independent from the study investigators.

497

## 498 **Ethical approval and trial registration**

499 The trial is registered with the UK Clinical Trials Registry (ISRCTN 10585019), and was approved by the  
500 South East Scotland Research Ethics Committee 01 and subsequently, governance approval by NHS  
501 Greater Glasgow and Clyde Research and Innovation. The authors confirm that all ongoing and related  
502 trials for this intervention are registered.

503

## 504 **Discussion**

505 Homelessness is a growing global public health problem associated with many adverse health outcomes,  
506 yet research in this sphere, particularly empirical evidence of multiple health, vulnerability factors, social  
507 care problems, and RCT evidence for collaborative health and social care interventions, remains sparse.<sup>2</sup>

508

509 The pilot PHOENix after overdose RCT aims to determine whether a subsequent definitive RCT of a  
510 Pharmacist and third sector homeless outreach worker intervention is merited. The basis for this is  
511 achievement of progression criteria comprising recruitment, retention, data collection, and establishment of

512 the pharmacist intervention together with any signal of reduction in emergency department presentations  
513 for overdoses or other causes.

514

515 Strengths of this pilot trial relate to its rigorous design including embedded qualitative process and  
516 economic evaluations. The intervention is complex, and phases of complex intervention testing are being  
517 followed. The intervention is aligned with best practice recommendations in relation to assertive outreach,  
518 integrated health and social care support, providing longer appointments to enable patients to discuss their  
519 multiple issues. The extensive characterization of the patient population, recruited from 20 different  
520 locations in Scotland's largest city, ensures a cross section of PEH. Follow up is longer than most previous  
521 RCTs in homelessness. Outcomes are diverse, covering progression criteria for a subsequent randomised  
522 controlled trial, health care utilization, and objective and subjective health measures. However, limitations  
523 relate to the fact that this pilot trial is being conducted in Scotland only, with a population of PEH that may  
524 not be ethnically diverse. High levels of refusal to study participation and dropout leading to low numbers  
525 at 6 and 9 month follow up could also potentially threaten the generalizability of study results but we will  
526 be monitoring and reporting on this.

527

528 The PHOENIX pilot randomised controlled trial will provide new data and if objectives are met, seeks to  
529 inform a subsequent definitive trial aiming to reduce ED presentations for non-prescription drug overdose  
530 and other reasons, by strengthening primary health and social care in the community. It will also provide  
531 new knowledge about the characteristics of this patient population in terms of: the extent, nature of and  
532 treatment uptake for multimorbidity; non-prescribed drug use; uptake of primary and secondary health and  
533 social care; welfare benefits; treatment burden; subjective and objective measures of health including  
534 quality of life; laboratory results; and the prevalence of frailty to help inform future clinical trials and service  
535 delivery in this area.

536

537

538 **Declaration of interests**

539 Suitably anonymised and summarised data will be made available on reasonable request.

540

541 **Access to data**

542 The principal investigator, researchers and independent statisticians will have access to the final trial  
543 dataset.

544

545 **Dissemination policy**

546 Trial results will first be communicated to participants individually, verbally or in writing, through existing  
547 homelessness networks and accommodation providers. Healthcare, social care and third sector workers  
548 involved in the trial (GPs, ED staff, addictions staff and others) will receive a written summary of findings  
549 with an offer to meet the Principal Investigator to discuss the results. Health and Social care / Homelessness  
550 staff with a role in policymaking will receive a summary of results, and an offer of meeting to discuss any  
551 implications. The study findings will be described by all of the research team in accordance with guidelines  
552 for eligibility of authorship and submitted for publishing in a peer reviewed journal. There are no plans to  
553 involve professional writers.

554

555 **End of study date**

556 Processes for NHS research governance approvals were delayed during COVID-19 lockdown, leading to a  
557 delay in the trial start date. The end-of-study date is on the last day of 9 month follow up data collection  
558 (July 2022). Allowing time for data input to the trial database, summary and analysis, the final results will  
559 be available in the last quarter of 2022.

560

561 **Conclusion**

562 We expect this pilot RCT aimed at PEH with recent non-prescription drug overdose will determine whether  
563 a full RCT is justified and to provide valuable insights into the health and social care needs of this

564 marginalised population, while providing a signal of whether the complex PHOENIX health and social care  
565 intervention improves outcomes.

566

567 **Funding**

568 NHS Greater Glasgow and Clyde and the Drug Deaths Task Force, Scottish Government. The study  
569 design, funding, staff and governance are independent from commercial sponsorship of any kind.

570



